Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...

A small ge­net­ic test­ing start­up backed by Pe­ter Thiel’s Founders Fund and Red­dit co-founder Alex­is Ohan­ian’s 776 Fund ...

The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

Apellis has had its European ambitions dashed once again after regulators reaffirmed their decision to not recommend the ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.

Amer­i­cans can now vac­ci­nate them­selves against the flu with­out the as­sis­tance of a health­care work­er.

Sanofi released new Phase 3 data for its BTK inhibitor tolebrutinib in non-relapsing secondary progressive multiple sclerosis ...

Novo Nordisk has ended one of the multiple trials testing the lead oral drug from its $1.1 billion Forma Therapeutics buyout, ...